Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal